Follow-up Author Response: Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy

We are grateful for the additional response on our research.1 Regarding the readers’ inquiry as to whether the study population was representative of clinical practice in small fiber neuropathy (SFN), we would like to point out that the median exclusion rates in RCTs is approximately 77%,2 which is in line with our study. In 53% of the SFN population, no underlying condition was found,3 which is a large proportion of clinical patients. The aim of our study was to investigate IVIg treatment in these patients.

Read article at journal's website

Related Articles

Responses

Your email address will not be published.